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Background: Recurrent tuberculosis (TB) following TB treatment completion in HIV-infected 
individuals remains a major public health burden. We assessed the role of various risk factors in 
mediating the development of recurrent TB and subsequent resistance to antiretroviral therapy 
and anti-TB drugs.
Patients and methods: We analyzed secondary demographic, clinical, and laboratory data 
from medical records of five HIV-infected TB patients enrolled between 2009 and 2014 in a 
prospective observational study investigating TB recurrence. Paired clinical isolates of Myco-
bacterium tuberculosis were typed by IS6110 restriction fragment length polymorphism analysis 
to determine the mechanism of TB recurrence. Plasma samples were genotyped to determine 
acquisition of HIV drug resistance mutations on antiretroviral treatment (ART).
Results: All five patients were HIV-coinfected, with a previous history of TB infection and 
prior exposure to anti-TB treatment, and residual lung damage, and demonstrated poor treat-
ment adherence – significant risk factors linked to the development of recurrent TB disease. 
Furthermore, three of the five patients had multiple episodes of drug-susceptible TB infection 
with subsequent drug-resistant TB infection. Genotyping of the initial and recurrent M. tuber-
culosis isolates demonstrated three cases of recurrent TB because of relapse and two because 
of reinfection. All five patients had no mutations at ART initiation; however, by the end of the 
study follow-up, all patients developed dual class resistance.
Conclusion: This series demonstrates the complexity of recurrent TB in HIV coinfection. 
We highlight the challenges of managing coinfected patients and the increased propensity for 
the development of drug resistance. We report on the role of various risk factors mediating the 
development of resistance and subsequent clinical impact. This report underscores the need 
for structural clinical and adherence interventions for the management of complex treatment 
and dosing.
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Introduction
Globally, tuberculosis (TB) presents as the most common opportunistic infection 
in people with HIV.1 In the latest global TB report, the World Health Organization 
estimated that 10% of the 10.4 million incident cases of TB in 2016 were coinfected 
with HIV. Sub-Saharan Africa bears the highest rates of HIV-associated TB, with 
coinfection rates of up to 50% in some areas.1 In HIV-uninfected individuals with 
latent TB infection, the lifetime risk of TB reactivation disease is 10%. This risk is 
increased to 10% per annum in HIV-infected patients.2 In addition to the increased 
risk of TB reactivation, HIV coinfection has also been reported as a significant risk 
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factor for recurrent TB disease. Weakened immune responses, 
a hallmark characteristic of HIV infection, facilitates the 
progression to active TB disease and is a significant risk 
factor for recurrent TB disease.3 HIV–TB coinfection is 
further complicated by the development of drug resistance 
in Mycobacterium tuberculosis.4–6
Recurrent TB disease, following cure or successful treat-
ment completion, occurs as a result of either relapse (recur-
rence of the previous infection) or reinfection (infection with 
a new strain type), each associated with its own risk factors. 
Risk factors associated with individual vulnerability includ-
ing immune compromise due to comorbidities such as HIV 
coinfection and diabetes mellitus, residual lung damage due 
to previous TB infection, age, malnutrition, and social risk 
factors such as alcohol abuse and cigarette smoking have been 
attributed to both relapse and reinfection. Risk factors that 
impact on treatment response such as inadequate treatment 
regimen, poor treatment adherence, and unrecognized drug 
resistance or host-specific factors that affect drug metabolism 
have been attributed to relapse of TB disease. Increased risk 
due to poor epidemic or infection control resulting in repeat 
exposure has been attributed to reinfection. Distinguishing 
between relapse and reinfection requires comparing the 
homology of M. tuberculosis strains isolated during the first 
and recurrent TB episodes using molecular-based DNA 
fingerprinting techniques.7,8
Complex multi-drug regimens and optimal medication 
adherence are required for effective treatment of TB/HIV 
coinfection.9–11 This results in challenges of adherence to 
complex dosing strategies, long duration of therapy, serious 
and often life-threatening drug side effects, and drug–drug 
interactions.11 Adherence, a major factor undermining treat-
ment outcomes, relies on patients’ attitude, knowledge, and 
beliefs, which are in turn influenced by poverty, gender, 
stigma, and other social and cultural factors.9–14 Patients 
failing TB treatment are likely to remain infectious thereby 
increasing the likelihood of ongoing transmission of infec-
tion.9,15,16 We report and analyze five patients with HIV–TB 
coinfection, receiving concomitant treatment for both 
diseases and who subsequently developed recurrent drug-
resistant TB (DR-TB). This report highlights the various risk 
factors that contributed to the development of recurrent TB.
Patients and methods
We conducted a retrospective chart review on a subset of 
patients enrolled in the CAPRISA TRuTH study investigating 
the incidence of TB recurrence in adult TB/HIV-coinfected 
patients, who previously completed treatment for drug-sensitive 
pulmonary TB in the CAPRISA SAPiT trial.17 The study was 
conducted between June 2005 and August 2013. Patients were 
followed up quarterly for 5 years. Among 82 patients who devel-
oped recurrent TB, five patients were diagnosed with recurrent 
DR-TB. Case notes were used to report the contributing risk 
factors to the development of recurrent TB.
Patients diagnosed were treated with standard TB treat-
ment, and treatment outcomes were recorded as per the 
South African National TB control program guidelines.18 
Patients were initiated on a once-daily first-line antiretrovi-
ral treatment (ART) regimen and managed as per national 
guidelines.19 Participants received TB treatment adherence 
– counseling occurred prior to TB treatment initiation, and 
adherence was enhanced and verified through TB directly 
observed therapy short-course (DOTS) program. ART 
adherence support occurred through group counseling, two 
sessions prior to initiation, one on the day of treatment, and 
continued six-monthly thereafter. Adherence was assessed by 
clinic-based pill count at all scheduled visits, and six-monthly 
virologic outcomes. Adherence was described according to 
previously published categories by medication possession 
ratios and patient self-reporting.
To determine the mechanism mediating TB recurrence, 
initial and recurrent isolates were genotyped using the IS6110 
restriction fragment length polymorphism method.22,23 To 
assess the impact of HIV on TB recurrence, HIV virologic 
markers were assessed and stored plasma samples were 
analyzed for drug resistance conferring mutations prior to 
ART initiation, at the entry of the TRuTH study, and at the 
end of the study. HIV drug resistance sequencing incor-
porated the viral protease (codons 1–99) and reverse tran-
scriptase (codons 1–230) genes. Drug resistance mutations 
were interpreted using the Stanford University HIV drug 
resistance database16,18 and the International AIDS Society 
mutation list.19
Ethical approval for the TRuTH study was obtained 
from the University of KwaZulu-Natal Biomedical Ethics 
Research Committee, reference number BF051/09; Clinical 
trials number NCT01539005. Written informed consent was 
obtained from all participants to publish case details and 
images with no personal identifiers.
Results
In-depth clinical profiles for each patient are described in 
Table 1. The mean age was 34.8 (range, 30–38) years during 
the first TB episode. Among the five participants, two were 
female and three were male. One patient displayed a body 
mass index (BMI) of 17.0, falling within the underweight 
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Table 1 Epidemiologic and clinical characteristics of five patients with recurrent (M) XDR-TB following drug-susceptible TB
Clinical and epidemiologic 
biomarker
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
age 38 32 38 36 30
gender M M F F F
BMI  
BMI at TB-1 diagnosis 19.4 18.7 17.6 21.4 26
BMI at TB-1 end 18.4 20.5 18.7 23.2 26.5
BMI at TB-2 diagnosis 21.3 20.4 17.0 19.4 25.8
Initial episode of TB  
Date and method of diagnosis Jul 2007
X-ray + sputum
Jul 2007
X-ray + sputum
Jan 2007
X-ray + sputum
nov 2007
X-ray + sputum
aug 2005
X-ray + sputum
genetic and susceptibility 
profile
Beijing
Ds-TB
F15/laM4/KZn 
Ds-TB
lymph aspirate 
resistant to Inh 
and RIF
F28
Ds-TB
F28
Ds-TB
Unique
Ds-TB
chest radiograph Infiltrates on 
Rl; cavities and 
infiltrates on LL
Infiltrates on RL 
and ll
cavities, 
infiltrates, 
pleural disease, 
and shrinkage 
and destruction 
in Rl, minimal 
fibrosis on LL
cavities and 
infiltrates in RL 
and ll
cavities and 
infiltrates in RL 
and ll
completion date, duration on 
treatment and outcome
1 april 2008
8 months
cure
20 March 2008
8 months
cure
20 august 2007
10 months
cure
Jun 30 2008
7 months
cure
02 January 06
6 months
cure
chest radiograph at the end 
of treatment
Fibrosis in upper 
Rl
Fibrosis in ll Extensive fibrosis not available not available
Recurrent MDR/XDR episode 
of TB
 
Mechanism of recurrence, 
genetic profile of TB isolates 
and time to recurrence
Reinfection
Beijing to KZn 
strain
24 months
Relapse
KZn strain
28 months
Reinfection
F28 – unique
19 months
Relapse
F28 strain
28 months
Relapse
Unique strain
15 months
Date and method of diagnosis June 10
X-ray + sputum 
culture
Feb 2011
X-ray + sputum
apr 2010
X-ray + sputum 
culture
nov 2010
X-ray + sputum
May 07
X-ray + sputum
Susceptibility profile XDR-TB
Resistant to 
Inh, RIF, eMB, 
kanamycin, 
capreomycin, OFX, 
Ialiamide, sM, eTh, 
and PZa
MDR-TB
Resistant to Inh, 
RIF, eMB, eTh, 
PZa, and sM
MDR-TB
Resistant to nh, 
RIF, eTh, sM, 
and PZa
MDR-TB
Resistant to Inh, 
eMB, RIF, sM, eTh, 
and PZa
XDR-TB
Inh, RIF, eMB, 
MXF, Kana, 
and eTh
Radiologic findings Infiltrates on RL 
and infiltrates and 
new lesions on ll
cavities in ll Bullae and plural 
effusion in Rl
cavities and 
infiltrates on RL 
and fibrosis on LL
cavitation in ll
Treatment outcome Transferred out for 
DR-TB care
Transferred out for 
DR-TB care
Died Withdrew from 
study
Transferred out 
for DR-TB care
hIV history  
Date of diagnosis Jul 2007 Jul 2007 Jan 2007 Dec 2007 2005
Treatment regimen aZT/3Tc/eFV, 
switched aZT to 
TDF in May 2009
ddI/3Tc/eFV 
(discontinued 
between March and 
april 2009)
ddI/3Tc/eFV ddI/3Tc/eFV 
switched to aBc/
TDF/lPV/r in 
October 2008, and 
back to regimen 1 
in June 2011
ddI/3Tc/eFV, 
switched to 
TDF in July 
2011
(Continued)
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range during the recurrent TB episode. The remaining 
patients recorded BMI values in the normal range.
TB history and associated risk 
factors for recurrent TB
All five patients had a previous history of TB disease for 
which they received between 6 and 10 months of DS anti-TB 
treatment, before enrolling into the TRuTH study. Patients 1 
and 5 subsequently developed XDR-TB, and the remaining 
patients developed MDR-TB. Patients 1, 2, and 3 presented 
with DR-TB in the TRuTH study 24, 28, and 19 months, 
respectively, after successful treatment completion for two 
prior episodes of DS-TB. Patients 4 and 5 presented with 
DR-TB during the TRuTH study 28 and 15 months, respec-
tively, after successful treatment completion for one episode 
of DS-TB. Assessment of radiographic chest X-rays during 
initial TB infection, point of cure for initial TB episode, 
and TB relapse (Figures S1–S4 and Table 1) indicated that 
recurrent TB infection was characterized by the presence of 
vast damage to the lungs and residual damage from prior TB 
infection. Month 2 sputum culture results were only available 
for patients 1 and 2, both of which remained positive. The 
remaining patients had only sputum smear results available, 
all of which were negative. Among the paired M. tuberculosis 
isolates representing the initial and recurrent TB episodes, 
there were two cases of TB reinfection (patients 1 and 3) and 
three cases of TB relapse (patients 2, 4, and 5). Detailed data 
on genetic profiles, drug susceptibility profiles, and timelines 
for recurrent disease episodes are reported in Table 1.
HIV coinfection and its impact on 
recurrent TB disease
All five patients were diagnosed with HIV at screening of 
the SAPiT trial and initiated on standard treatment at vari-
ous points during concomitant anti-TB therapy. The mean 
CD4+ T cell count was 171 cells/mm3 at diagnosis of the 
initial TB episode, 341,2 cells/mm3 at cure of the first TB 
episode and 289 cells/mm3 at diagnosis of recurrent TB. 
CD4 and viral load data for each patient are detailed in Table 
1. Retrospective analysis of HIV drug resistance mutations 
demonstrated that the patients had no pre-ART drug resis-
tance mutations. However, over the course of treatment and 
Table 1 (Continued)
Clinical and epidemiologic 
biomarker
Patient 1 Patient 2 Patient 3 Patient 4 Patient case 5
Regimen response Virologic 
suppression; 
sustained high 
cD4+ cell count
Raised cD4 count 
and virologic 
suppression by 
Month 12
good virologic 
suppression, 
cD4 cell count 
remained low
Failed both 
regimens, placed 
back onto Regimen 
1
good virologic 
suppression, 
cD4 count 
remained low
cD4/Vl at initial TB diagnosis cD4 =200
Vl =260,000
cD4 =54
Vl =126,000
cD4 =151
Vl =41,663
cD4 =245
Vl = Unavailable
cD4 =205
Vl =83,900
CD4/VL at the end of first TB 
episode
cD4 =434
Vl =400
cD4 =377
Vl ≤400
cD4 =331
Vl ≤400
cD4 =212
Vl =27,400
cD4 =352
Vl ≤400
cD4/Vl at recurrent TB 
diagnosis
cD4 =3,652
Vl = unavailable
cD4 =565
V ≤400
cD4 =245
Vl ≤40
cD4 =143
Vl =20,302
cD4 =204
Vl =69,400
Other notes  
TB risk profile hospitalization hospitalization hospitalization household TB 
contacts
no risks
Adherence profile Poor; adherence 
support program
Fair; missed 
clinic visits due 
to alcohol use, 
occasional missing 
of doses
good Poor; 
hospitalization 
for supervised TB 
treatment
good
Other medical conditions anemia, Pn, sn, 
hepB
IRIs on TB 
treatment, Pn
Pn, pneumonia 
in august 2010
hypertension, Pn none
substance use history alcohol abuse, 
smoking
alcohol abuse, 
smoking
none none none
Notes: Initial episode of TB = TB-1; Recurrent episode of TB = TB-2 radiological findings from chest x-rays conducted after diagnosis and treatment end (closest date 
available given).
Abbreviations: 3Tc, lamivudine; aBc, abacavir; alV, alluvia; aZT, azidothymidine; BMI, body mass index; cD4, cD4+ T-cell count (cells/µl3); DDI, didanosine; eFV, 
efavirenz; EMB, ethambutol; ETH, ethionamide; Hep B, hepatitis B; INH, isoniazid; LL, left lung; MDR, multi-drug-resistant; OFX, ofloxacin; PN, peripheral neuropathy; PTB, 
pulmonary TB; PZa, pyrazinamide; R4, Rifafour; RIF, rifampicin; Rl, right lung; sM, streptomycin; sn, sensory neuropathy; TB, tuberculosis; TDF, tenofovir; Vl, viral load 
(copies/µl3); XDR, extensively drug-resistant. 
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subsequent regimen changes, by the end of the study all 
patients developed dual class resistance with non-nucleoside 
reverse transcriptase inhibitor (NNRTI) mutations featuring 
prominently. Protease inhibitor resistance mutations were not 
detected in any of the patients described. Detailed data on all 
resistance-associated mutations over the course of treatment 
are shown in Table 2.
adherence and social risk factors
There were various social risk factors and treatment adher-
ence issues that played a role in the complex clinical course 
of these patients. Patient 1 had a history of alcohol abuse 
resulting in poor adherence, missed clinic visits, and dis-
continuation of ART for a period of 6 months. The patient’s 
hospital admission also coincided with diagnosis of his 
recurrent TB episode. Patient 2 also had a reported history 
of alcohol abuse resulting in poor adherence and incarcera-
tion that coincided with his MDR-TB diagnosis. Patient 3 
reported that her partner was HIV positive who was not 
on ART and declined condom use with her. In addition, 
this patient reported a low level of educational attainment. 
Patient 4 displayed poor adherence despite receiving intensive 
counseling under study conditions. She also reported close 
contacts with TB patients, no condom use, and low level 
of educational attainment. Patient 5 reported no significant 
adherence or social risk factors.
Discussion
This series highlights the impact of various risk factors in the 
development of recurrent TB infection in five HIV-coinfected 
patients. We further highlight the considerable complexity 
in the management of coinfected patients because of the use 
of multiple drugs with complex dosing schedules, and pro-
longed treatment course that is often complicated by severe 
overlapping drug toxicities. Published data from various 
settings consistently demonstrate the impact of these factors 
on patient adherence and retention in care.20,21,24,25
Notwithstanding the small sample size in this case 
series, the following important findings should be noted. 
All five patients were HIV coinfected with a previous 
history of TB infection and prior exposure to anti-TB 
treatment, residual lung damage, and demonstration of 
poor treatment adherence; significant risk factors linked 
to the development of recurrent TB disease. Furthermore, 
three of the five patients had multiple episodes of DS-TB 
infection with subsequent DR-TB infection. Strain typing 
revealed that recurrence occurred by relapse in three cases 
and by reinfection in two cases. While published reports 
attribute reinfection as the main mechanism of recurrence 
in the context of HIV coinfection, we demonstrated three 
cases of relapse in our study among HIV/TB-coinfected 
patients.26–29 Furthermore, our data support findings of a 
recent South African study showing ongoing transmission 
of DR-TB, and the low rates of TB culture conversion 
including frequent reversion.6
We retrospectively analyzed the development of ART 
resistance mutations in our recurrent TB patients. Despite 
having no mutations at ART initiation, by the end of the 
study all five patients developed dual class resistance with 
NNRTI mutations featuring prominently. The considerable 
pill burden imposed by the addition of DR-TB treatment 
to chronic ART is likely to have negatively impacted ART 
adherence fueling development of ART resistance. These 
findings are consistent with the published surveillance 
studies conducted in this setting, reporting the mutations 
detected in this study as prevalent mutations associated with 
acquired resistance in adults.15,30–34 Retrospective analysis of 
the resistance mutations reveals that patients were receiving 
inadequate ART for optimal viral suppression. Furthermore, 
guidelines advocate first-line ART regimen switch without 
the benefit of ART resistance testing. This coupled with the 
lack of objective markers of ART adherence comprises early 
detection and management of ART failure. Most impor-
tantly, these cases highlight the need for ongoing clinical 
monitoring for treatment failure and HIV resistance testing, 
especially in patients taking complex regimen for multiple 
concurrent conditions.
Suboptimal adherence to treatment was a key factor 
driving drug resistance in this subset of patients. Despite 
receiving enhanced counseling support under clinical trial 
conditions, patients remained nonadherent. In keeping with 
previous reports, known behavioral and biologic risk factors 
such as alcohol misuse, incarceration, hospital admission, 
poor pill-taking behavior, low level of education attainment, 
and missed clinic appointments featured among patients fail-
ing treatment and acquiring resistance in this study. Despite 
access to free care for both HIV and TB, underlying social 
issues severely impacted treatment outcomes underscoring 
the need for strong ongoing support directed at optimizing 
treatment adherence and treatment completion.9,14,16,35–39 
DOTS programs played a pivotal role in increasing treatment 
completion rates globally. Adopting a similar strategy for the 
management of DR-TB and HIV coinfection could impact 
on reducing recurrent TB rates.40–42 As reinfection rates are 
higher in HIV endemic settings like South Africa, we also 
highlight the need for enhanced infection control measures 
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and ongoing surveillance in congregate settings such as clinic 
waiting rooms, hospitals, and prisons.43,44
We would like to acknowledge study limitations. Sec-
ondary study data and stored samples from the study bio-
repository were analyzed. We had to rely on self-reported 
information regarding prior ARV treatment and ART and TB 
adherence. The lack of availability of objective markers of 
adherence undermines our ability to understand the evolution 
of drug resistance to ART and TB drugs. Furthermore, the 
small sample size limits the generalizability of our findings to 
other patients and settings. We also did not establish if these 
patients had mixed strain infection and the extent to which 
this might have influenced our findings.
In conclusion, the cases described in this series highlight 
the public health crisis resulting from the intersecting epidem-
ics of DR-TB and drug-resistant HIV. The study underscores 
the complexity of managing TB and HIV coinfection, and 
the impact of various risk factors in mediating resistance. 
Patients failing treatment present a public health risk of 
ongoing transmission of resistant strains. Distinguishing 
between relapse and reinfection plays an invaluable role in 
addressing the burden of recurrent TB disease. High rates 
of relapse underscore the need for renewed interventions to 
improve individual patient care while high rates of reinfection 
underscore the need for improved epidemic control measures. 
Urgent attention is also required to address challenges of 
adherence, such as social and health care worker support 
systems and step-down management facilities. Enhanced 
treatment options, such as intensified initial treatment, 
extension of treatment, and preventative therapy for patients 
presenting with multiple risk factors, will prevent recurrent 
TB infection. The heightened risk of recurrent TB in ART 
programs underscores the need for regular TB screening at 
ART follow-up visits .There has been considerable disparity 
in the studies reporting on the role of relapse vs reinfection. 
Further large-scale studies are required to address the role 
of relapse and reinfection as well as the role of mixed infec-
tions in recurrent TB.
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Supplementary materials
Chest radiographs for Patients 1–4 (no images available for 
Patient 5).
A B C
Figure S1 chest X-rays of Patient 1 depicting (A) infiltrates on both lungs; (B) persistent fibrosis in the left lung; and (C) cavities in the left lung.
A B C
Figure S2 chest X-rays of Patient 2 depicting (A) infiltrates in both lungs and cavities in the left lung; (B) right upper lobe fibrosis; and (C) infiltrates in the right lung and 
infiltrates and new lesions in the left lung.
A B C
Figure S3 chest X-rays of Patient 3 depicting (A) cavities and infiltrates in both lungs; (B) cavities and infiltrates on the right lung and fibrosis in the left lung; and (C) cavities, 
infiltrates, and patchy consolidation in the right lung and consolidation in mid and lower zones of the left lung.
Figure S4 chest X-rays of Patient 4 depicting (A) vast damage to the right lung with cavities, infiltrates, pleural disease, shrinkage, and destruction. Minimal damage to the 
left lung; (B) residual widespread damage to the right lung; and (C) right lung bullae and new pleural effusion. New infiltrates in left lung. 
A B C
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